ADPT חוב כולל להון Adaptive Biotechnologies Inc.

Current price action for Adaptive Biotechnologies (ADPT) reflects a debt-to-equity ratio of 3.02. Adaptive Biotechnologies leads the field of immune analysis, attracting top geneticists and bioinformaticians through its innovative developments. A high barrier to entry is maintained by a robust patent portfolio and the complexity of certification. Business growth is driven by an alliance with a cloud behemoth and the joint development of tests with the largest pharmaceutical companies.

This ratio determines the proportion of borrowed funds relative to equity, where the current value of 3.02 reflects the degree of financial leverage and the risk of dependence on creditors. Analyzing the business's leverage ratio allows for an assessment of Adaptive Biotechnologies (ADPT) and its ability to finance costly FDA validation and AI developments without a critical debt burden, which is essential for maintaining stability within a stringent regulatory environment.